Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bacchetti

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Cell|August 22, 1997
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalizationM Meyerson, C M Counter, E N Eaton, et al.
British Journal of Cancer|July 15, 2010
Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastasesM Cosimelli, R Golfieri, P P Cagol, et al.
Molecular Endocrinology (Baltimore, Md.)|November 5, 2011
Silencing of GSTP1, a prostate cancer prognostic gene, by the estrogen receptor-β and endothelial nitric oxide synthase complexA Re, A Aiello, S Nanni, et al.
In Vivo (Athens, Greece)|January 6, 2007
A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response ratesR Mancini, L Carpanese, R Sciuto, et al.
Nature Biotechnology|April 20, 1999
Telomere-dependent senescenceD Kipling, D Wynford-Thomas, C J Jones, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Cell|August 22, 1997
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalizationM Meyerson, C M Counter, E N Eaton, et al.
British Journal of Cancer|July 15, 2010
Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastasesM Cosimelli, R Golfieri, P P Cagol, et al.
Molecular Endocrinology (Baltimore, Md.)|November 5, 2011
Silencing of GSTP1, a prostate cancer prognostic gene, by the estrogen receptor-β and endothelial nitric oxide synthase complexA Re, A Aiello, S Nanni, et al.
In Vivo (Athens, Greece)|January 6, 2007
A multicentric phase II clinical trial on intra-arterial hepatic radiotherapy with 90yttrium SIR-spheres in unresectable, colorectal liver metastases refractory to i.v. chemotherapy: preliminary results on toxicity and response ratesR Mancini, L Carpanese, R Sciuto, et al.
Nature Biotechnology|April 20, 1999
Telomere-dependent senescenceD Kipling, D Wynford-Thomas, C J Jones, et al.
Pageof 10